发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
BACKGROUND:The management of disseminated cysticercosis is unclear and largely considered hazardous. The role of albendazole remains controversial in such patients. METHODS:A tertiary care, University hospital-based prospective intervention study was conducted from December 2015 to December 2017. Patients with disseminated cysticercosis, defined as the presence of multiple viable neurocysticerci (≥ 3) in the brain along with involvement of an additional extra site, were included in the study. Patients with cysticercal encephalitis were excluded. A detailed evaluation, including ophthalmoscopy, ocular B scans, ultrasound abdomen, and X-rays were done. Albendazole was administered at a dose of 15 mg/kg/day in 3 cycles of 28 days each. All patients were also given adjuvant corticosteroids and anti-epileptic drugs. Clinical and radiological follow up was carried out at a difference of 3 months between each treatment cycle. For radiological quantification, lesions were counted at 10 pre-specified levels. Statistical analysis was done to estimate the difference in seizure frequency and lesion load. RESULTS:Twenty-nine patients (21 with > 20 lesions; 8 with ≤ 20 lesions) were given albendazole as per the protocol. There was a significant reduction in the occurrence of seizures (P < 0.001) and headache (P < 0.001). A significant reduction in lesion load from baseline to third follow-up was seen in the estimations done at different levels (P < 0.001). No patient developed serious side-effect warranting cessation of therapy. CONCLUSION:Cyclical use of albendazole appears efficacious in treating disseminated cysticercosis. The method of quantification described may be used in future studies for objective assessment. TRIAL REGISTRATION:ISRCTN11630542; 28th September 2019; Retrospectively registered.
展开更多
最新影响因子:3.667 | 期刊ISSN:1471-2334 | CiteScore:2.86 |
出版周期:Irregular | 是否OA:YES | 出版年份:2001 |
自引率:4.70% | 研究方向:医学-传染病学 |
出版地区:ENGLAND |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Published by BioMed Central. ISSN: 1471-2334. BMC Infectious Diseases publishes original research articles in all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases, as well as related molecular genetics, pathophysiology, and epidemiology.
由生物医学中心出版。ISSN: 1471 - 2334。 BMC传染病在传染病和性传播疾病的预防、诊断和管理,以及相关的分子遗传学、病理生理学和流行病学的所有方面发表原创研究文章。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
INFECTIOUS DISEASES (传染病学) 3区 |
44/88 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
794 | 746 | 48 |
引文计数(2018)
文献(2015-2017)
6069次引用
2124篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Infectious Diseases
|
#64/266
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
liting7111
研究方向:免疫
审稿时间: 6个月内 接受率: 比较困难(25%命中)
liting7111
liting7111
接受率: 一般容易(75%命中)
liting7111
liting7111
liting7111
liting7111
liting7111
研究方向:感染
审稿时间: 3个月内 接受率: 中等(50%命中)
liting7111
研究方向:肝病 免疫
审稿时间: 2个月内 接受率: 中等(50%命中)
liting7111
liting7111
研究方向:感染与免疫
liting7111
研究方向:肺损伤 缺血缺氧脑病
审稿时间: 2个月内 接受率: 一般容易(75%命中)
liting7111
liting7111
审稿时间: 3个月内 接受率: 中等(50%命中)
影响因子:1.696
ISSN:0174-304X
研究方向:医学-临床神经学
影响因子:4.21
ISSN:0887-8994
研究方向:医学-临床神经学
影响因子:2.363
ISSN:0883-0738
研究方向:医学-临床神经学
影响因子:3.042
ISSN:1071-9091
研究方向:CLINICAL NEUROLOGY-PEDIATRICS
影响因子:3.692
ISSN:1090-3798
研究方向:医学-临床神经学
影响因子:4.864
ISSN:0012-1622
研究方向:医学-临床神经学
影响因子:9.703
ISSN:0031-4005
研究方向:医学-小儿科
影响因子:5.106
ISSN:1661-7800
研究方向:医学-小儿科
影响因子:2.567
ISSN:1471-2431
研究方向:PEDIATRICS-
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
BMC INFECTIOUS DISEASES 投稿经验
(由下方点评分析获得,15人参与,61114人阅读)